Ferroptosis: A New Therapeutic Vulnerability in Cancer

For decades, cancer treatment has been built upon a relatively simple principle: eliminating malignant cells by inducing apoptosis. Surgery removes the tumor, chemotherapy damages rapidly dividing cells, and radiotherapy creates irreparable DNA injury. Yet one of the greatest challenges in modern oncology is that many cancer cells eventually acquire mechanisms that allow them to evade apoptosis, leading to treatment resistance and disease recurrence. This limitation has driven the search for alternative forms of regulated cell death, among which ferroptosis has emerged as one of the most promising.

Ferroptosis is an iron-dependent form of regulated cell death characterized by the progressive accumulation of lipid peroxides that ultimately destroy the cell membrane. Unlike apoptosis, it is independent of caspase activation and DNA fragmentation. Instead, it results from the inability of the cell to control oxidative stress generated by iron metabolism. The recent review published in Signal Transduction and Targeted Therapy identifies ferroptosis as one of the most promising emerging mechanisms for the treatment of breast cancer.

Iron plays a paradoxical role in tumor biology. It is indispensable for mitochondrial respiration, DNA synthesis, and cellular proliferation, which explains why cancer cells increase their iron uptake to sustain rapid growth. However, this metabolic dependence also creates an important vulnerability. Ferrous iron (Fe²⁺) catalyzes the generation of reactive oxygen species through the Fenton reaction, producing highly reactive radicals that attack polyunsaturated fatty acids within the cell membrane. This initiates a cascade of lipid peroxidation. Once oxidative damage exceeds the cell’s antioxidant defenses, membrane integrity is irreversibly compromised, triggering ferroptotic cell death.

The principal defense against this process is glutathione peroxidase 4 (GPX4). This enzyme detoxifies lipid hydroperoxides before they reach lethal concentrations. As long as GPX4 remains functional, cells can survive despite substantial oxidative stress. Conversely, inhibition of GPX4 leads to rapid lipid peroxide accumulation and ferroptotic cell death. The review highlights GPX4 as a central regulator of ferroptosis and reports that GPX4 inhibitors reduce tumor growth while enhancing antitumor immune responses in experimental models of breast cancer.

Importantly, susceptibility to ferroptosis is not uniform across all breast cancer subtypes. The review notes that the Luminal Androgen Receptor (LAR) subtype of triple-negative breast cancer exhibits particularly high ferroptosis activity, suggesting that certain tumors may be especially vulnerable to therapies designed to exploit this metabolic weakness. The authors also describe an emerging interaction between ferroptosis and the immune system. Induction of ferroptosis appears to enhance antitumor immunity, and combining GPX4 inhibition with immunotherapy produced greater suppression of tumor growth in preclinical studies than either strategy alone.

Although current evidence remains largely preclinical, ferroptosis represents a significant conceptual shift in oncology. Rather than focusing exclusively on inhibiting cell proliferation or inducing apoptosis, this strategy targets a fundamental metabolic dependency of cancer cells. In this context, iron is no longer viewed solely as an essential nutrient that supports tumor growth, but also as a potential therapeutic vulnerability capable of driving selective tumor cell death. Should ongoing clinical research confirm the encouraging experimental findings, ferroptosis may become an important component of future cancer therapy, offering new opportunities to overcome treatment resistance and improve outcomes for patients with breast cancer.